Clinical Trial Update: Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer [Phase 2]

View source ↗

Summary

Phase II trial of tunlametinib in NRAS-mutant advanced thyroid cancer is currently recruiting, evaluating differentiated, poorly differentiated, and anaplastic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Thyroid Carcinoma
• Differentiated Thyroid Cancer
• Poorly Differentiated Thyroid Carcinoma

Drugs mentioned

• Tunlametinib (tunlametinib)

Snippet

Sponsor: Fudan University | Conditions: Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS Mutation, Advanced PDTC or ATC With NRAS Mutation | Phase 2 | Status: RECRUITING